Monsanto announced that it has reached a new global licensing agreement with the Broad Institute of MIT and Harvard for the use of the novel CRISPR-Cpf1 genome-editing technology in agriculture. The CRISPR-Cpf1 system represents an ...
Tags: Monsanto, Crispr System
Food products developer Calyxt is generating healthier high-oleic low-linolenic soybean variety with increased oxidative stability and improved shelf life. The company published a study in BMC Plant Biology describing the use of genome ...
Tags: Calyxt, low-linolenic soybean
Monsanto Company has announced that it has reached a global licensing agreement for the use of the CRISPR-Cas genome-editing technology in agriculture with the Broad Institute of MIT and Harvard. The Broad Institute is a world leader in ...
It may seem like mosquitoes will bite anything with a pulse, but they're actually quite strategic in picking their victims. A new study from The Rockefeller University looked at the interaction of different sensory cues—carbon ...
Tags: Electronics, CO2
Work uncovers secret of how genome-editing tool works as a 'guided missile' to correct errors in the genetic code Researchers from the Broad Institute and MIT have teamed up with colleagues from the University of Tokyo to form the first ...
Biogen Idec (NASDAQ: BIIB) and Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that ...
Editas Medicine, a transformative genome editing company, today announced it has secured a $43m Series A financing led by Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund. ...
Tags: Editas Medicine, genome editing
Sangamo BioSciences has received a $6.4m strategic partnership grant from the California Institute for Regenerative Medicine (CIRM) for the development of ZFP Therapeutic for Beta-thalassemia. The application of its zinc finger nuclease ...
Tags: Sangamo, ZFG Therapeutic